142 related articles for article (PubMed ID: 9744310)
21. Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy.
Khoo VS; Pollack A; Cowen D; Joon DL; Patel N; Terry NH; Zagars GK; von Eschenbach AC; Meistrich ML; Troncoso P
Prostate; 1999 Nov; 41(3):166-72. PubMed ID: 10517874
[TBL] [Abstract][Full Text] [Related]
22. High Inter- and Intratumoral Variability of Ki67 Labeling Index in Newly Diagnosed Prostate Cancer with High Gleason Scores.
Vlajnic T; Brunner P; Eppenberger-Castori S; Rentsch CA; Zellweger T; Bubendorf L
Pathobiology; 2022; 89(2):74-80. PubMed ID: 34555829
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens.
Rubio J; Ramos D; López-Guerrero JA; Iborra I; Collado A; Solsona E; Almenar S; Llombart-Bosch A
Eur Urol; 2005 Nov; 48(5):745-51. PubMed ID: 16139948
[TBL] [Abstract][Full Text] [Related]
24. High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer.
Lobo J; Rodrigues Â; Antunes L; Graça I; Ramalho-Carvalho J; Vieira FQ; Martins AT; Oliveira J; Jerónimo C; Henrique R
Urol Oncol; 2018 Apr; 36(4):161.e7-161.e17. PubMed ID: 29174711
[TBL] [Abstract][Full Text] [Related]
25. Combined analysis with Bcl-2 and P53 immunostaining predicts poorer prognosis in prostatic carcinoma.
Matsushima H; Kitamura T; Goto T; Hosaka Y; Homma Y; Kawabe K
J Urol; 1997 Dec; 158(6):2278-83. PubMed ID: 9366376
[TBL] [Abstract][Full Text] [Related]
26. Prognostic relevance of apoptotic cell death in non-Hodgkin's lymphomas: a multivariate survival analysis including Ki67 and p53 oncoprotein expression.
Korkolopoulou P; Angelopoulou MK; Kontopidou F; Tsenga A; Patsouris E; Thomas-Tsagli E; Kittas C; Pangalis GA
Histopathology; 1998 Sep; 33(3):240-7. PubMed ID: 9777390
[TBL] [Abstract][Full Text] [Related]
27. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting.
Borre M; Stausbol-Gron B; Overgaard J
J Urol; 2000 Sep; 164(3 Pt 1):716-21. PubMed ID: 10953132
[TBL] [Abstract][Full Text] [Related]
28. The correlation between the immunostains for p53 and Ki67 with bcl-2 expression and classical prognostic factors in colorectal carcinomas.
Gurzu S; Jung J; Mezei T; Pávai Z
Rom J Morphol Embryol; 2007; 48(2):95-9. PubMed ID: 17641794
[TBL] [Abstract][Full Text] [Related]
29. p53 and bcl-2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy.
Oxley JD; Winkler MH; Parry K; Brewster S; Abbott C; Gillatt DA
BJU Int; 2002 Jan; 89(1):27-32. PubMed ID: 11849156
[TBL] [Abstract][Full Text] [Related]
30. Expression of p53, Bcl-2, VEGF, Ki67 and PCNA and prognostic significance in hepatocellular carcinoma.
Stroescu C; Dragnea A; Ivanov B; Pechianu C; Herlea V; Sgarbura O; Popescu A; Popescu I
J Gastrointestin Liver Dis; 2008 Dec; 17(4):411-7. PubMed ID: 19104702
[TBL] [Abstract][Full Text] [Related]
31. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates.
Nakopoulou L; Vourlakou C; Zervas A; Tzonou A; Gakiopoulou H; Dimopoulos MA
Hum Pathol; 1998 Feb; 29(2):146-54. PubMed ID: 9490274
[TBL] [Abstract][Full Text] [Related]
32. [The role of repeated biopsies in prognosis of prostate cancer].
Romics I; Lovász S; Szabó J; Szomor L; Minik K; Bartók K; Kerényi T; Szende B
Orv Hetil; 2002 Jul; 143(27):1619-23. PubMed ID: 12179998
[TBL] [Abstract][Full Text] [Related]
33. [p53 and Ki67 expression in specimens of radical prostatectomy. Relationship with clinico-pathologic data and survival].
Zudaire Bergera JJ; Sánchez Zalabardo D; Arocena García-Tapia J; Sanz Pérez G; Díez Caballero F; López Ferrandis J; Rosell Costa D; Robles García JE; de Alava E; Berián Polo JM
Actas Urol Esp; 2000 Apr; 24(4):307-13. PubMed ID: 14964088
[TBL] [Abstract][Full Text] [Related]
34. Expression of p53 and bcl-2 in clinically localized prostate cancer before and after neo-adjuvant hormonal therapy.
Cesinaro AM; Migaldi M; Ferrari G; Castagnetti G; Dotti A; De Gaetani C; Ferrari P; Trentini GP
Oncol Res; 2000; 12(1):43-9. PubMed ID: 11061345
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of Ki-67 expression in advanced prostate cancers in relation to disease progression after androgen ablation.
Matsuura H; Hayashi N; Kawamura J; Shiraishi T; Yatani R
Eur Urol; 2000 Feb; 37(2):212-7. PubMed ID: 10705201
[TBL] [Abstract][Full Text] [Related]
36. Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma.
Szende B; Romics I; Minik K; Szabó J; Torda I; Lovász S; Szomor L; Tóth L; Bély M; Kerényi T; Bartók K; Végh A
Prostate; 2001 Oct; 49(2):93-100. PubMed ID: 11582587
[TBL] [Abstract][Full Text] [Related]
37. [Survival of patients with laryngeal cancer and some prognostic factors].
Gryczyński M; Kobos J; Murlewska A; Pietruszewska W
Otolaryngol Pol; 2003; 57(3):329-40. PubMed ID: 14524174
[TBL] [Abstract][Full Text] [Related]
38. Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder.
Moonen L; Ong F; Gallee M; Verheij M; Horenblas S; Hart AA; Bartelink H
Int J Radiat Oncol Biol Phys; 2001 Apr; 49(5):1305-10. PubMed ID: 11286838
[TBL] [Abstract][Full Text] [Related]
39. Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance.
Josefsson A; Wikström P; Egevad L; Granfors T; Karlberg L; Stattin P; Bergh A
Scand J Urol Nephrol; 2012 Aug; 46(4):247-57. PubMed ID: 22452635
[TBL] [Abstract][Full Text] [Related]
40. Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population.
Inoue T; Segawa T; Shiraishi T; Yoshida T; Toda Y; Yamada T; Kinukawa N; Kinoshita H; Kamoto T; Ogawa O
Urology; 2005 Aug; 66(2):332-7. PubMed ID: 16098362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
